Evidence map›Paper›PMID 27374183›Full record

ReviewThe surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland2017

Pancreatic cancer actionable genes in precision medicine and personalized surgery.

Juehua Yu, Shi-He Liu, Robbi Sanchez, John Nemunaitis, Enrique Rozengurt, F Charles Brunicardi

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in The surgeon : journal of the Royal Colleges of Surgeons of Edinburgh and Ireland, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.6field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Juehua YuDivision of General Surgery, Department of Surgery, David Geffen School of Medicine at University of California Los Angeles, CA, USA.
Shi-He LiuDivision of General Surgery, Department of Surgery, David Geffen School of Medicine at University of California Los Angeles, CA, USA.
Robbi SanchezDivision of General Surgery, Department of Surgery, David Geffen School of Medicine at University of California Los Angeles, CA, USA.
John NemunaitisMary Crowley Cancer Research Center, Dallas, TX, USA.
Enrique RozengurtDepartment of Medicine, David Geffen School of Medicine at University of California Los Angeles, CA, USA.
F Charles BrunicardiDivision of General Surgery, Department of Surgery, David Geffen School of Medicine at University of California Los Angeles, CA, USA. Electronic address: cbrunicardi@mednet.ucla.edu.
University of California, Los Angeles · USMary Crowley Cancer Research Center · US

Funding

Pilot and Feasibility ProgramP30DK041301 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 1990 to 2019
$18.0M
Targeting diet-induced promotion of Kras-initiated pancreatic adenocarcinomaP01CA163200 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI PANDOL, STEPHEN J. · 2012 to 2016
$6.2M
PDX-1 is a Therapeutic Target for Pancreatic CancerR01CA095731 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BRUNICARDI, FRANCIS CHARLES · 2002 to 2012
$2.6M
Intraislet Communication in Surgically-Altered PancreasR01DK046441 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI BRUNICARDI, FRANCIS CHARLES · 1998 to 2007
$1.9M
PKD1 Signaling and Crosstalk Mechanisms in Intestinal Epithelial Cell RegulationR01DK100405 · NIDDK · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ROZENGURT, JUAN ENRIQUE · 2014 to 2017
$1.3M
NCI NIH HHS P01 CA163200NCI NIH HHS R01 CA095731NIDDK NIH HHS P30 DK041301NIDDK NIH HHS R01 DK046441NIDDK NIH HHS R01 DK100405
6 · The paper itself

Abstract

Pancreatic ductal adenocarcinoma (PDAC) is a deadly cancer with an overall 5-year survival rate less than 5% due to the poor early diagnosis and lack of effective therapeutic options. The most effective therapy remains surgery, however post-operative survival could be enhanced with effective adjuvant therapy. The massive information gained from Omics techniques on PDAC at the beginning of the 21st century is a remarkable accomplishment. However, the information gained from the omics data, including next generation sequencing data, has yet to successfully affect care of patients suffering with PDAC. Therefore, we propose the development of an actionable genomic platform that matches a patient's PDAC clinically actionable genes with potential targeted adjuvant therapies. Using this platform, PDX1 has been identified as a potential actionable gene for PDAC, therefore, RNAi therapy, gene therapy and small inhibitory drugs, all targeting PDX1, serve as potential targeted adjuvant therapies. Preclinical studies support the hypothesis that identification of PDAC actionable genes could permit translation of a patient's genomic information into precision targeted adjuvant therapy for PDAC.

Indexed as

Precision MedicineAdenocarcinomaHumansPancreatic NeoplasmsActionable genesMolecular surgeryPancreatic cancer

Identifiers

PMID27374183
PMCPMC5195911
OpenAlexW2465504768

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.